-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
NanoFlu investigational vaccine
Therapeutic area | Infectious disease | Status | Technology |
---|---|---|---|
Respiratory diseases | Seasonal influenza | Phase 3 | Matrix-M™ adjuvant |
Therapeutic area
Respiratory diseases
Infectious disease
Seasonal influenza
Status
Phase 3
Technology
Matrix-M™ adjuvant
About the candidate
NanoFlu is our quadrivalent nanoparticle influenza vaccine (qNIV) candidate, targeting seasonal flu. NanoFlu is designed using our recombinant technology, with 4 forms of wild-type hemagglutinin (HA) protein from the influenza virus as antigens. Antigens are organized into distinct nanoparticle complexes recognized by the immune system, working in concert with our Matrix-M™ adjuvant.
Why it matters
Seasonal influenza is a significant global burden, with up to 650,000 flu-related deaths each year around the world.1 Current influenza vaccines have several limitations.2 A new generation of vaccines is needed to offer protection from disease.
In a successful phase 3 trial in the United States, NanoFlu met all of its endpoints.3
- Influenza – estimating burden of disease. WHO. Available at: https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/seasonal-influenza/burden-of-influenza [Accessed 3 Sept 2021].
- Soema P, et al. Eur J Biopharm. 2015;95:251–263.
- Shinde V, et al. Lancet Infect Dis. Sept 2021. doi: https://doi.org/10.1016/S1473-3099(21)00192-4. [Accessed 2 Feb 2022]